ENHERTU gains first-ever nod in China for metastatic breast cancer
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
Full approval will depend on verification of clinical benefit in a confirmatory trial
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
NUFYMCO BLA has been approved by the USFDA
The company also reported significant progress toward its internally defined Sustainable Development Goals
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Subscribe To Our Newsletter & Stay Updated